Abstract
Introduction: HMV is widely used to treat chronic respiratory failure. The aim of this study was to describe the initial HMV setup and subsequent outcome based on diagnostic group.
Methods: Retrospective study from bespoke prospective database entry, including all patients setup on HMV at the Lane Fox Respiratory Unit in London from 1st January 2008 to 31st December 2014.
Results: 1135 patients were set up on HMV. 22% (n:249) neuromuscular disease (NMD), 9% (n:99) chest wall disease (CWD); 23% (n:258) obstructive airway disease (OAD); 12% (n:139) hypercapnic obstructive sleep apnea (OSA); 28% (n:317) OSA-Obesity hypoventilation syndrome (OHS), 5% (n:60) COPD-OSA, 1% (n:13) other conditions. HMV setups increased from 116 in 2008 to 212 in 2014. Baseline data are reported in fig. 1.
Cumulative survival differed with underlying disease.
5 year survival was 57% for NMD, 59% for CWD, 31% for OAD, 79% for OSA-OHS, 73% for OSA, 63% for COPD-OSA, 26% for other conditions
Conclusion: Demand for HMV is increasing with OAD, having the poorest outcome and OSA-OHS having the best outcome at 5 years. Of clinical importance, COPD-OSA overlap patients have an improved outcome compared with COPD patients.
- Copyright ©ERS 2015
